{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-280741","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.099498+00:00","generated_at":"2026-06-22T01:45:24.009199+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Phathom Pharma Q3 net loss $51.1M, NERD trial enrollment complete","bullets":["Net loss of $51.1M in Q3 2022 vs. $36.7M in Q3 2021; R&D expense $19.0M, G&A $23.5M.","Cash and equivalents $196.8M at Sep 30, 2022; additional $100M available under term loan.","Completed enrollment in Phase 3 NERD daily dosing trial (776 patients); topline data expected Q1 2023.","Secured up to $40M additional non-dilutive financing under revenue interest agreement; total capacity $300M.","Planned Q1 2023 U.S. launches of VOQUEZNA TRIPLE PAK, DUAL PAK, and if approved, VOQUEZNA for EE."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-280741","json":"https://secwatch.observer/filing/0001193125-22-280741.json","markdown":"https://secwatch.observer/filing/0001193125-22-280741.md","text":"https://secwatch.observer/filing/0001193125-22-280741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312522280741/0001193125-22-280741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312522280741/d412146d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:45:24.009199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3aac163cce0b12432ab38e1ee454bb63cea1b479","claim":"Phathom Pharmaceuticals, Inc. reported the third quarter of 2022 results: net income Net loss for the third quarter ended September 30, 2022, was $51.1 million, compared to $36.7 million for third quarter.","evidence_excerpt":"On November 8, 2022, Phathom Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312522280741/0001193125-22-280741-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Net income","value":"Net loss for the third quarter ended September 30, 2022, was $51.1 million, compared to $36.7 million for third quarter"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}